Geode Capital Management LLC Acquires 34,248 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Geode Capital Management LLC raised its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 8.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 455,637 shares of the company’s stock after purchasing an additional 34,248 shares during the quarter. Geode Capital Management LLC’s holdings in UroGen Pharma were worth $5,787,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of UroGen Pharma by 90.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after acquiring an additional 3,856 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after purchasing an additional 5,890 shares during the last quarter. ProShare Advisors LLC purchased a new position in shares of UroGen Pharma in the 2nd quarter worth approximately $199,000. Intech Investment Management LLC bought a new position in shares of UroGen Pharma during the 3rd quarter valued at approximately $155,000. Finally, Verition Fund Management LLC purchased a new stake in UroGen Pharma during the 3rd quarter valued at $168,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Stock Performance

UroGen Pharma stock opened at $11.21 on Friday. UroGen Pharma Ltd. has a fifty-two week low of $10.26 and a fifty-two week high of $20.70. The company has a market capitalization of $262.92 million, a PE ratio of -3.56 and a beta of 1.09. The company has a 50 day moving average price of $11.73 and a 200-day moving average price of $13.55. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to analysts’ expectations of $24.22 million. During the same quarter in the prior year, the company posted ($0.68) earnings per share. As a group, equities analysts forecast that UroGen Pharma Ltd. will post -3.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

URGN has been the topic of a number of analyst reports. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. Oppenheimer reiterated an “outperform” rating and set a $40.00 price target on shares of UroGen Pharma in a report on Wednesday, October 16th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of UroGen Pharma in a research note on Tuesday, October 15th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Friday, December 6th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, UroGen Pharma has a consensus rating of “Buy” and a consensus target price of $43.70.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.